CN Patent

CN117534672A — 一种apds治疗药物新的制备方法

Assigned to Beijing Kang Lisheng Pharmaceutical Technology Development Co ltd · Expires 2024-02-09 · 2y expired

What this patent protects

本发明提供一种经2步反应制备高纯度的莱尼利西布的新方法，其显著特点是路线短，产品纯度高，收率高，操作安全简单，环境友好。该新路线有助于降低莱尼利西布的生产成本，缓解其可及性问题，使中国磷酸肌醇3激酶δ过度活化综合征(APDS)患者从中获益。

USPTO Abstract

本发明提供一种经2步反应制备高纯度的莱尼利西布的新方法，其显著特点是路线短，产品纯度高，收率高，操作安全简单，环境友好。该新路线有助于降低莱尼利西布的生产成本，缓解其可及性问题，使中国磷酸肌醇3激酶δ过度活化综合征(APDS)患者从中获益。

Drugs covered by this patent

Patent Metadata

Patent number
CN117534672A
Jurisdiction
CN
Classification
—
Expires
2024-02-09
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Kang Lisheng Pharmaceutical Technology Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.